Cytoreductive surgery alone or combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei [PDF]
, 2018 This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The aim of this work is to evaluate the efficacy of cytoreductive surgery alone versus cytoreductive surgery in combination with hyperthermic intraperitoneal ...
Ma, Huaixing +7 more
core +1 more source
Efficacy and safety in the use of intraperitoneal hyperthermia chemotherapy and peritoneal cytoreductive surgery for pseudomyxoma peritonei from appendiceal neoplasm: A systematic review [PDF]
, 2022 The objective of this systematic review is to provide efficacy and safety data in the application of Intra-Abdominal Hyperthermia Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) in patients with Peritoneal Pseudomyxoma (PMP) of origin in the cecal ...
Bernardo, Wanderley Marques +4 more
core +2 more sources
Journal of Natural Products, 2021 While marine natural products have been investigated for anticancer drug discovery, they are barely screened against rare cancers. Thus, in our effort to discover potential drug leads against the rare cancer pseudomyxoma peritonei (PMP), which currently ...
Zhuo Shang +15 more
semanticscholar +1 more source
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin - 801 Cases from a Single Institution in China [PDF]
, 2020 Aim: As more and more centers has published their treatment results ofpseudomyxoma peritonei (PMP) with cytoreductive surgery (CRS) andhyperthermic intraperitoneal chemotherapy (HIPEC), the data from Chinais missing.
An, Lubiao +10 more
core +2 more sources
Journal of Surgical Oncology, 2021 Pseudomyxoma peritonei (PMP) is a rare disease, with the rate of overall survival (OS) influenced by many factors. The present study aimed to define independent predictors and establish a nomogram for individual risk prediction in PMP patients.
Mingjian Bai +8 more
semanticscholar +1 more source
World Journal of Surgical Oncology, 2004 Background Pseudomyxoma peritonei is a rare condition consisting of mucinous ascites, most commonly arising from mucinous tumors of the appendix and occasionally from the ovary. Very rarely mucinous implants arise in the retroperitoneum without any intra-
Solkar Mamoon H +3 more
doaj +1 more source
Aggressive Pseudomyxoma Peritonei: A Case Report with an Unusual Clinical Presentation [PDF]
, 2013 Introduction. Pseudomyxoma peritonei (PMP) is an uncommon surgical entity. We report a case of aggressive disease with an unusual clinical presentation and we analyze current data on diagnosis and management of PMP. Case Presentation.
Galyfos, George +4 more
core +1 more source
Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery
Colorectal Disease, 2021 Appendiceal pseudomyxoma peritonei (PMP) is a rare entity, with recurrence rates up to 26% despite optimal cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Joseph C. H. Kong +10 more
semanticscholar +1 more source
The management of pseudomyxoma peritonei [PDF]
Cancer, 1990 The management of nine patients with pseudomyxoma peritonei was reviewed. Aggressive surgical resection of tumor is the standard of treatment, with many patients requiring multiple laparotomies. Chemotherapy, including the use of cisplatin is not effective. Long-term nutritional support provides a better quality of survival for select patients.
John Chumas +3 more
openaire +3 more sources
Pseudomyxoma peritonei de origem appendicular Pseudomyxoma peritonei ex processu vermiformi
Memorias do Instituto Oswaldo Cruz, 1937 Os autores descrevem um caso de pseudomyxoma do peritoneo, originario do appendice ileo-cecal, em individuo do sexo masculino, de 58 anos de edade.
A. Penna de Azevedo +1 more
doaj +1 more source